[8-K] Olema Pharmaceuticals, Inc. Reports Material Event
Olema Pharmaceuticals reported its financial results for the quarter ended June 30, 2025 and furnished a press release and an investor presentation as exhibits to this Current Report. The filing identifies the press release as Exhibit 99.1, the investor presentation as Exhibit 99.2, and the cover page interactive data file as Exhibit 104. The company states these materials are being furnished and are not deemed "filed" under Section 18 of the Exchange Act.
The 8-K does not include numerical financial metrics within the text; investors seeking revenue, earnings, or other performance figures must review the attached Exhibit 99.1 press release or Exhibit 99.2 presentation or consult the company website where the presentation was made available.
Olema Pharmaceuticals ha comunicato i risultati finanziari per il trimestre chiuso il 30 giugno 2025 e ha fornito un comunicato stampa e una presentazione per gli investitori come allegati al presente Current Report. Il deposito indica il comunicato stampa come Exhibit 99.1, la presentazione come Exhibit 99.2 e il file dati interattivo della copertina come Exhibit 104. La società specifica che questi materiali sono forniti e non sono considerati "presentati" ai sensi della Section 18 dello Exchange Act.
L'8-K non contiene nel testo metriche finanziarie numeriche; gli investitori in cerca di dati su ricavi, utili o altri indicatori di performance devono consultare il comunicato allegato (Exhibit 99.1), la presentazione (Exhibit 99.2) o il sito web della società dove la presentazione è stata resa disponibile.
Olema Pharmaceuticals comunicó sus resultados financieros del trimestre terminado el 30 de junio de 2025 y adjuntó un comunicado de prensa y una presentación para inversores a este Current Report. El expediente identifica el comunicado como Exhibit 99.1, la presentación para inversores como Exhibit 99.2 y el archivo de datos interactivos de la portada como Exhibit 104. La compañía aclara que estos materiales se suministran y no se consideran "presentados" conforme a la Sección 18 del Exchange Act.
El Form 8-K no incluye cifras financieras numéricas en el texto; los inversores que busquen información sobre ingresos, beneficios u otros indicadores de rendimiento deben revisar el comunicado adjunto (Exhibit 99.1), la presentación (Exhibit 99.2) o consultar la página web de la compañía donde se publicó la presentación.
Olema Pharmaceuticals는 2025년 6월 30일로 종료된 분기의 재무 결과를 발표하고, 보도자료와 투자자 프레젠테이션을 이 Current Report의 첨부자료로 제공했습니다. 제출 문서에는 보도자료를 Exhibit 99.1, 투자자 프레젠테이션을 Exhibit 99.2, 표지의 대화형 데이터 파일을 Exhibit 104로 명시하고 있습니다. 회사는 이러한 자료들이 제공되는 것이며 Exchange Act의 Section 18에 따라 "제출된(filed)" 것으로 간주되지 않는다고 밝혔습니다.
이번 8-K 본문에는 수치화된 재무 지표가 포함되어 있지 않습니다. 매출, 수익 또는 기타 성과 수치를 확인하려면 첨부된 Exhibit 99.1 보도자료나 Exhibit 99.2 프레젠테이션을 보거나, 프레젠테이션이 게시된 회사 웹사이트를 참조해야 합니다.
Olema Pharmaceuticals a communiqué ses résultats financiers pour le trimestre clos le 30 juin 2025 et a fourni un communiqué de presse ainsi qu'une présentation pour les investisseurs en pièces jointes à ce Current Report. Le dépôt identifie le communiqué comme Exhibit 99.1, la présentation comme Exhibit 99.2 et le fichier de données interactif de la page de couverture comme Exhibit 104. La société précise que ces documents sont fournis et ne sont pas considérés comme "déposés" au sens de la Section 18 de l'Exchange Act.
Le formulaire 8-K n'inclut pas de chiffres financiers dans le corps du texte ; les investisseurs souhaitant connaître les revenus, bénéfices ou autres indicateurs de performance doivent consulter le communiqué joint (Exhibit 99.1), la présentation (Exhibit 99.2) ou le site web de la société où la présentation a été mise en ligne.
Olema Pharmaceuticals hat die Finanzergebnisse für das Quartal zum 30. Juni 2025 bekanntgegeben und eine Pressemitteilung sowie eine Investorenpräsentation als Anhänge zu diesem Current Report eingereicht. Die Einreichung bezeichnet die Pressemitteilung als Exhibit 99.1, die Präsentation als Exhibit 99.2 und die interaktive Titelseiten-Datendatei als Exhibit 104. Das Unternehmen weist darauf hin, dass diese Unterlagen bereitgestellt werden und gemäß Section 18 des Exchange Act nicht als "filed" gelten.
Der 8-K enthält im Text keine numerischen Finanzkennzahlen; Anleger, die Angaben zu Umsatz, Gewinn oder anderen Leistungskennzahlen suchen, müssen die beigefügte Pressemitteilung (Exhibit 99.1) oder die Präsentation (Exhibit 99.2) einsehen oder die Website des Unternehmens besuchen, auf der die Präsentation veröffentlicht wurde.
- Press release furnished (Exhibit 99.1) reporting quarter results, indicating formal disclosure to the market
- Investor presentation furnished (Exhibit 99.2) and made available on the company website to support investor review
- Interactive data file included (Exhibit 104), facilitating standardized access to cover page data
- None.
Insights
TL;DR: Routine disclosure furnishing quarterly results; no financial details are included in the 8-K itself.
The filing serves primarily to notify the market that Olema has released its quarter-end results and supporting investor materials. Because the 8-K text contains no revenue, EPS, cash flow, or guidance figures, there is no basis within this filing to assess operational performance or revalue forecasts. Material analysis requires reviewing Exhibit 99.1 and 99.2.
TL;DR: Communication-focused filing; exhibits and website posting improve accessibility but do not alter fundamentals.
Furnishing both a press release and an investor deck is consistent with standard disclosure practice and helps ensure broad distribution of results to shareholders and analysts. The distinction that materials are "furnished" rather than "filed" is typical and limits certain legal liabilities but does not change the availability of the disclosed content. Impact is informational rather than material in isolation.
Olema Pharmaceuticals ha comunicato i risultati finanziari per il trimestre chiuso il 30 giugno 2025 e ha fornito un comunicato stampa e una presentazione per gli investitori come allegati al presente Current Report. Il deposito indica il comunicato stampa come Exhibit 99.1, la presentazione come Exhibit 99.2 e il file dati interattivo della copertina come Exhibit 104. La società specifica che questi materiali sono forniti e non sono considerati "presentati" ai sensi della Section 18 dello Exchange Act.
L'8-K non contiene nel testo metriche finanziarie numeriche; gli investitori in cerca di dati su ricavi, utili o altri indicatori di performance devono consultare il comunicato allegato (Exhibit 99.1), la presentazione (Exhibit 99.2) o il sito web della società dove la presentazione è stata resa disponibile.
Olema Pharmaceuticals comunicó sus resultados financieros del trimestre terminado el 30 de junio de 2025 y adjuntó un comunicado de prensa y una presentación para inversores a este Current Report. El expediente identifica el comunicado como Exhibit 99.1, la presentación para inversores como Exhibit 99.2 y el archivo de datos interactivos de la portada como Exhibit 104. La compañía aclara que estos materiales se suministran y no se consideran "presentados" conforme a la Sección 18 del Exchange Act.
El Form 8-K no incluye cifras financieras numéricas en el texto; los inversores que busquen información sobre ingresos, beneficios u otros indicadores de rendimiento deben revisar el comunicado adjunto (Exhibit 99.1), la presentación (Exhibit 99.2) o consultar la página web de la compañía donde se publicó la presentación.
Olema Pharmaceuticals는 2025년 6월 30일로 종료된 분기의 재무 결과를 발표하고, 보도자료와 투자자 프레젠테이션을 이 Current Report의 첨부자료로 제공했습니다. 제출 문서에는 보도자료를 Exhibit 99.1, 투자자 프레젠테이션을 Exhibit 99.2, 표지의 대화형 데이터 파일을 Exhibit 104로 명시하고 있습니다. 회사는 이러한 자료들이 제공되는 것이며 Exchange Act의 Section 18에 따라 "제출된(filed)" 것으로 간주되지 않는다고 밝혔습니다.
이번 8-K 본문에는 수치화된 재무 지표가 포함되어 있지 않습니다. 매출, 수익 또는 기타 성과 수치를 확인하려면 첨부된 Exhibit 99.1 보도자료나 Exhibit 99.2 프레젠테이션을 보거나, 프레젠테이션이 게시된 회사 웹사이트를 참조해야 합니다.
Olema Pharmaceuticals a communiqué ses résultats financiers pour le trimestre clos le 30 juin 2025 et a fourni un communiqué de presse ainsi qu'une présentation pour les investisseurs en pièces jointes à ce Current Report. Le dépôt identifie le communiqué comme Exhibit 99.1, la présentation comme Exhibit 99.2 et le fichier de données interactif de la page de couverture comme Exhibit 104. La société précise que ces documents sont fournis et ne sont pas considérés comme "déposés" au sens de la Section 18 de l'Exchange Act.
Le formulaire 8-K n'inclut pas de chiffres financiers dans le corps du texte ; les investisseurs souhaitant connaître les revenus, bénéfices ou autres indicateurs de performance doivent consulter le communiqué joint (Exhibit 99.1), la présentation (Exhibit 99.2) ou le site web de la société où la présentation a été mise en ligne.
Olema Pharmaceuticals hat die Finanzergebnisse für das Quartal zum 30. Juni 2025 bekanntgegeben und eine Pressemitteilung sowie eine Investorenpräsentation als Anhänge zu diesem Current Report eingereicht. Die Einreichung bezeichnet die Pressemitteilung als Exhibit 99.1, die Präsentation als Exhibit 99.2 und die interaktive Titelseiten-Datendatei als Exhibit 104. Das Unternehmen weist darauf hin, dass diese Unterlagen bereitgestellt werden und gemäß Section 18 des Exchange Act nicht als "filed" gelten.
Der 8-K enthält im Text keine numerischen Finanzkennzahlen; Anleger, die Angaben zu Umsatz, Gewinn oder anderen Leistungskennzahlen suchen, müssen die beigefügte Pressemitteilung (Exhibit 99.1) oder die Präsentation (Exhibit 99.2) einsehen oder die Website des Unternehmens besuchen, auf der die Präsentation veröffentlicht wurde.
FAQ
What did Olema (OLMA) disclose in this 8-K?
Are the press release and investor presentation filed or furnished?
Where can I find the detailed financial figures for OLMA's quarter?
Which period do the disclosed results cover?
What exhibits were included with the 8-K?
Who signed the report on behalf of Olema?
